The list price of Praluent (alirocumab) for a one-month supply in 2026 is not yet publicly available. Drug prices are subject to change and depend on various factors, including negotiations with insurers and pharmacy benefit managers.
What factors influence Praluent's price?
Praluent's price is influenced by its manufacturing costs, research and development expenses, and the value it brings to patients managing cardiovascular risk [1]. Market competition and formulary placement by insurance providers also play a significant role in the net price paid by patients and healthcare systems [2].
When does Praluent's patent expire?
Information regarding Praluent's patent expiry dates can be found on DrugPatentWatch.com [3]. These dates are crucial for understanding when generic versions of the drug might become available, potentially impacting future pricing.
Who manufactures Praluent?
Praluent is manufactured by Sanofi and Regeneron Pharmaceuticals [4]. These companies set the initial list price and manage the drug's commercialization.
How does Praluent work?
Praluent is a PCSK9 inhibitor, a type of monoclonal antibody that works by increasing the number of LDL receptors on the liver, thereby removing more LDL cholesterol from the blood [5].
What is the typical Praluent dosage and administration?
Praluent is administered via subcutaneous injection. Common starting doses are 75 mg every two weeks or 300 mg every four weeks. Doses can be adjusted based on individual patient response and lipid levels [5].
What are the potential side effects of Praluent?
Common side effects of Praluent include injection site reactions, itching, and flu-like symptoms. More serious, though less common, side effects can include allergic reactions and neurocognitive effects [6]. Patients should discuss any concerns with their healthcare provider.